Trial Profile

A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of DT-216 in Adult Patients With Friedreich Ataxia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DT-216 (Primary)
Indications Friedreich's ataxia
Focus Adverse reactions
Sponsors Design Therapeutics

Most Recent Events

07 Dec 2022 According to a Design Therapeutics media release, the company will host a live webcast and conference call to discuss updates from the SAD and MAD trials.
07 Dec 2022 Results published in a Design Therapeutics media release.
08 Aug 2022 According to a Design Therapeutics media release, Initial Data from this trial of DT-216 Expected in the Fourth Quarter of 2022

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com